Opendata, web and dolomites

MISTRAL SIGNED

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MISTRAL project word cloud

Explore the words cloud of the MISTRAL project. It provides you a very rough idea of what is the project "MISTRAL" about.

cure    acquisition    immune    brings    2010    systemic    beings    millions    critical    resolved    full    ideal    27    team    incorporated    validate    risk    mitigate    eastern    diseases    accelerated    complications    mechanistically    streamlining    aging    applicable    tool    inflammation    resistance    antiretroviral    faced    treatment    irreversibly    efficacy    made    disorders    health    60    cloud    suggest    class    infection    deaths    curated    patient    drug    stratify    human    boost    pandemic    gut    soaring    chronic    interpretations    mistral    host    designed    interventions    immunotherapy    cancer    automate    regions    accessible    datasets    antimicrobial    hiv    microbiome    despite    unlock    rationally    biomarker    clinical    stratification    public    repository    continues    viral    closer    acquiring    immunotherapies    benefit    aids    expertise    complementary    outcome    web    therapeutic    successful    discoveries    software    biomarkers    mankind    infections    living    world    innovations    outcomes    science    inform    impacts    smes    purposes    discover   

Project "MISTRAL" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO PRIVADA INSTITUT DE RECERCA DE LA SIDA-CAIXA 

Organization address
address: CARRETERA DE CANYET
city: BARCELONA
postcode: 8916
website: www.irsicaixa.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 9˙994˙383 €
 EC max contribution 9˙994˙383 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2019-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO PRIVADA INSTITUT DE RECERCA DE LA SIDA-CAIXA ES (BARCELONA) coordinator 3˙967˙500.00
2    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 1˙490˙833.00
3    REGION HOVEDSTADEN DK (HILLEROD) participant 1˙017˙611.00
4    UNIVERSITE D'AIX MARSEILLE FR (Marseille) participant 730˙470.00
5    CASE WESTERN RESERVE UNIVERSITY CORPORATION US (CLEVELAND OHIO) participant 727˙787.00
6    AELIX THERAPEUTICS SL ES (BARCELONA) participant 534˙978.00
7    FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA ES (BARCELONA) participant 448˙021.00
8    CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER ES (BARCELONA) participant 351˙762.00
9    ASPHALION SL ES (BARCELONA) participant 316˙187.00
10    PROJECTE DELS NOMS - HISPANOSIDA ASOCIACION ES (BARCELONA) participant 236˙737.00
11    VEDANTA BIOSCIENCES INC US (WILMINGTON) participant 172˙493.00

Map

 Project objective

The HIV/AIDS pandemic continues to be one of the major health challenges ever faced by mankind. Far from being resolved, HIV is soaring in Eastern Europe (60% increase in new infections and 27% increase in deaths since 2010) and other regions of the world despite increasing access to antiretroviral treatment. There is emerging evidence that the human microbiome impacts some of the most important clinical aspects of HIV-1 infection, including immune disorders, chronic inflammation and accelerated aging. Work in other viral diseases and cancer immunotherapy suggest a critical role of the human microbiome also in the outcome of immune therapeutic interventions in HIV-1 infection. The MISTRAL project brings together a team of world-class HIV and microbiome researchers and SMEs with ideal complementary knowledge and expertise. This team will work to discover and validate novel gut microbiome biomarkers to inform rationally-designed, mechanistically-driven interventions on the gut microbiome to mitigate HIV-1 acquisition, systemic inflammation, chronic clinical complications, antimicrobial drug resistance, and boost the efficacy of HIV cure immunotherapies. Integrated and curated large microbiome and host datasets generated during the execution of the project will be made public through a freely accessible, specifically-dedicated web-based repository. Biomarker discoveries will be incorporated into a cloud-based software tool that will automate microbiome analyses and interpretations, thus streamlining patient stratification for clinical and research purposes. If successful, MISTRAL will benefit millions of human beings living with, or at risk of acquiring HIV-1 infection, and will produce novel concepts and technical innovations applicable to other human diseases. By doing that, MISTRAL will help to unlock the full clinical potential of the human microbiome to stratify patient outcomes and will irreversibly bring microbiome science closer to clinical practice.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MISTRAL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MISTRAL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ISLET (2020)

Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

VANGUARD (2020)

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Read More